Therapeutic options in recurrent glioblastoma-An update

Critical Reviews in Oncology/Hematology

Volumn 99, Issue , 2016, Pages 389-408

  Seystahl, Katharina ^a   Wick, Wolfgang ^b   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bevacizumab; Glioblastoma; Immunotherapy; MGMT; Nitrosourea; Temozolomide

Indexed keywords

6 O METHYLGUANINE; AFATINIB; AFLIBERCEPT; BEVACIZUMAB; BORTEZOMIB; CARMUSTINE; CEDIRANIB; ENZASTAURIN; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; FOTEMUSTINE; GALUNISERTIB; GEFITINIB; LAPATINIB; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; NINTEDANIB; NITROSOUREA; PANOBINOSTAT; PAZOPANIB; PLACEBO; SAGOPILONE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VORINOSTAT; ANTINEOPLASTIC AGENT;

BONE MARROW TOXICITY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL PRACTICE; CONTROLLED STUDY; FATIGUE; GLIOBLASTOMA; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INTENTION TO TREAT ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR VOLUME; WOUND HEALING IMPAIRMENT; BRAIN NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROGNOSIS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 84959284470     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.01.018     Document Type: Review

References (146)

1. Addeo R., Caraglia M., De Santi M.S., Montella L., Abbruzzese A., Parlato C., et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J. Neurooncol. 2011, 102:417-424.
2. Balmaceda C., Peereboom D., Pannullo S., Cheung Y.K., Fisher P.G., Alavi J., et al. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 2008, 112:1139-1146.
3. Barbagallo G.M., Jenkinson M.D., Brodbelt A.R. 'Recurrent' glioblastoma multiforme, when should we reoperate. Br. J. Neurosurg. 2008, 22:452-455.
4. Batchelor T.T., Duda D.G., di Tomaso E., Ancukiewicz M., Plotkin S.R., Gerstner E., et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 2010, 28:2817-2823.
5. Batchelor T.T., Mulholland P., Neyns B., Nabors L.B., Campone M., Wick A., et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J. Clin. Oncol. 2013, 31:3212-3218.
6. Bennouna J., Sastre J., Arnold D., Osterlund P., Greil R., Van Cutsem E., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013, 14:29-37.
7. Berrocal A., Perez Segura P., Gil M., Balana C., Garcia Lopez J., Yaya R., et al. Extended-schedule dose-dense temozolomide in refractory gliomas. J. Neurooncol. 2010, 96:417-422.
8. Bloch O., Han S.J., Cha S., Sun M.Z., Aghi M.K., McDermott M.W., et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J. Neurosurg. 2012, 117:1032-1038.
9. Bloch O., Crane C.A., Fuks Y., Kaur R., Aghi M.K., Berger M.S., et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014, 16:274-279.
10. Bonekamp D., Deike K., Wiestler B., Wick W., Bendszus M., Radbruch A., et al. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: comparison of intraindividually matched T1 - and T2 (*) - based bolus techniques. J. Magn. Reson. Imaging 2015, 42:87-96.
11. Brada M., Hoang-Xuan K., Rampling R., Dietrich P.Y., Dirix L.Y., Macdonald D., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 2001, 12:259-266.
12. Brada M., Stenning S., Gabe R., Thompson L.C., Levy D., Rampling R., et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J. Clin. Oncol. 2010, 28:4601-4608.
13. Brandes A.A., Ermani M., Basso U., Amista P., Berti F., Scienza R., et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann. Oncol. 2001, 12:255-257.
14. Brandes A.A., Ermani M., Basso U., Paris M.K., Lumachi F., Berti F., et al. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 2002, 63:38-41.
15. Brandes A.A., Tosoni A., Amista P., Nicolardi L., Grosso D., Berti F., et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004, 63:1281-1284.
16. Brandes A.A., Basso U., Reni M., Vastola F., Tosoni A., Cavallo G., et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J. Clin. Oncol. 2004, 22:1598-1604.
17. Brandes A.A., Tosoni A., Basso U., Reni M., Valduga F., Monfardini S., et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncol. 2004, 22:4779-4786.
18. Brandes A.A., Tosoni A., Cavallo G., Bertorelle R., Gioia V., Franceschi E., et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br. J. Cancer 2006, 95:1155-1160.
19. Brandes A.A., Tosoni A., Franceschi E., Blatt V., Santoro A., Faedi M., et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother. Pharmacol. 2009, 64:769-775.
20. Brandes A.A., Carpentier A.F., Kesari S., Sepulveda J.M., Wheeler H., Chinot O., et al. A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma. J. Clin. Oncol. 2015, 33:33. (suppl; abstr 2014).
21. Cabrera A.R., Cuneo K.C., Desjardins A., Sampson J.H., McSherry F., Herndon J.E., et al. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86:873-879.
22. Chamberlain M.C., Grimm S., Phuphanich S., Recht L., Zhu J.Z., Kim L., et al. A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC). J. Neurooncol. 2014, 118:335-343.
23. Chan D.T., Poon W.S., Chan Y.L., Ng H.K. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. Hong Kong Med. J. 2005, 11:452-456.
24. Chua S.L., Rosenthal M.A., Wong S.S., Ashley D.M., Woods A.M., Dowling A., et al. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol. 2004, 6:38-43.
25. Combs S.E., Debus J., Schulz-Ertner D. Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer 2007, 7:167.
26. Combs S.E., Edler L., Rausch R., Welzel T., Wick W., Debus J. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol. 2013, 52:147-152.
27. Desjardins A., Reardon D.A., Coan A., Marcello J., Herndon J.E., Bailey L., et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012, 118:1302-1312.
28. Dhermain F., de Crevoisier R., Parker F., Cioloca C., Kaliski A., Beaudre A., et al. Role of radiotherapy in recurrent gliomas. Bull. Cancer 2004, 91:883-889.
29. de Groot J.F., Lamborn K.R., Chang S.M., Gilbert M.R., Cloughesy T.F., Aldape K., et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 2011, 29:2689-2695.
30. Ellingson B.M., Sahebjam S., Kim H.J., Pope W.B., Harris R.J., Woodworth D.C., et al. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. AJNR Am. J. Neuroradiol. 2014, 35:673-679.
31. Ellingson B.M., Bendszus M., Boxerman J., Barboriak D., Erickson B.J., Smits M., et al. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol. 2015, 17:1188-1198.
32. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343:1350-1354.
33. Fabrini M.G., Silvano G., Lolli I., Perrone F., Marsella A., Scotti V., et al. A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 2009, 92:79-86.
34. Field K.M., Simes J., Nowak A.K., Cher L., Wheeler H., Hovey E.J., et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol. 2015, 17:1504-1513.
35. Flieger M., Ganswindt U., Schwarz S.B., Kreth F.W., Tonn J.C., la Fougere C., et al. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J. Neurooncol. 2014, 117:337-345.
36. Fogh S.E., Andrews D.W., Glass J., Curran W., Glass C., Champ C., et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J. Clin. Oncol. 2010, 28:3048-3053.
37. Franceschi E., Bartolotti M., Tosoni A., Bartolini S., Sturiale C., Fioravanti A., et al. The effect of re-operation on survival in patients with recurrent glioblastoma. Anticancer Res. 2015, 35:1743-1748.
38. Friday B.B., Anderson S.K., Buckner J., Yu C., Giannini C., Geoffroy F., et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 2012, 14:215-221.
39. Friedman H.S., Prados M.D., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:4733-4740.
40. Galanis E., Jaeckle K.A., Maurer M.J., Reid J.M., Ames M.M., Hardwick J.S., et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 2009, 27:2052-2058.
41. Galanis E., Anderson S.K., Lafky J.M., Uhm J.H., Giannini C., Kumar S.K., et al. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin. Cancer Res. 2013, 19:4816-4823.
42. Galanis E., Keith Anderson S., Anastasiadis P., Tran D.D., Jeyapalan S.A., Anderson D.M., et al. NCCTG N0872 (Alliance): a randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM). J. Clin. Oncol. 2015, 33. (suppl; abstr 2004).
43. Galldiks N., Dunkl V., Stoffels G., Hutterer M., Rapp M., Sabel M., et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET. Eur. J. Nucl. Med. Mol. Imaging 2015, 42:685-695.
44. Gan H., Fichtel L., Lassman A., Merrell R., van den Bent M., Kumthekar P., et al. A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). J. Clin. Oncol. 2015, 32:5s. (suppl; abstr 2021).
45. Gaviani P., Salmaggi A., Silvani A. Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. J. Neurooncol. 2011, 104:617-618.
46. Ghiaseddin A., Reardon D., Massey W., Mannerino A., Lipp E.S., Herndon J.E., et al. Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. J. Clin. Oncol. 2015, 33. (suppl; abstr 2034).
47. Gilbert M.R., Wang M., Aldape K.D., Lassman A.B., Sorensen A.G., Mikkelson T., et al. RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J. Clin. Oncol. 2009, 27. (suppl; abstr 2011).
48. Gilbert M.R., Kuhn J., Lamborn K.R., Lieberman F., Wen P.Y., Mehta M., et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J. Neurooncol. 2012, 106:147-153.
49. Gorlia T., Stupp R., Brandes A.A., Rampling R.R., Fumoleau P., Dittrich C., et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur. J. Cancer 2012, 48:1176-1184.
50. Grosu A.L., Weber W.A., Franz M., Stark S., Piert M., Thamm R., et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:511-519.
51. Groves M.D., Puduvalli V.K., Gilbert M.R., Levin V.A., Conrad C.A., Liu V.H., et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br. J. Cancer 2009, 101:615-620.
52. Guyotat J., Signorelli F., Frappaz D., Madarassy G., Ricci A.C., Bret P. Is reoperation for recurrence of glioblastoma justified. Oncol. Rep. 2000, 7:899-904.
53. Han S.J., Rolston J.D., Molinaro A.M., Clarke J.L., Prados M.D., Chang S.M., et al. Phase II trial of 7days on/7days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014, 16:1255-1262.
54. Hasselbalch B., Lassen U., Hansen S., Holmberg M., Sorensen M., Kosteljanetz M., et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010, 12:508-516.
55. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
56. Hovey E., Field K., Rosenthal M., Nowak A., Cher L., Wheeler H. Continuing or ceasing bevacizumab at disease progression: results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma. J. Clin. Oncol. 2015, 33. (suppl; abstr 2003).
57. Hundsberger T., Brugge D., Putora P.M., Weder P., Weber J., Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J. Neurooncol. 2013, 112:133-139.
58. Hunn M.K., Bauer E., Wood C.E., Gasser O., Dzhelali M., Ancelet L.R., et al. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. J. Neurooncol. 2015, 121:319-329.
59. Iwamoto F.M., Lamborn K.R., Robins H.I., Mehta M.P., Chang S.M., Butowski N.A., et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010, 12:855-861.
60. Johnson D.R., O'Neill B.P. Glioblastoma survival in the United States before and during the temozolomide era. J. Neurooncol. 2012, 107:359-364.
61. Keime-Guibert F., Chinot O., Taillandier L., Cartalat-Carel S., Frenay M., Kantor G., et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med. 2007, 356:1527-1535.
62. Khan R.B., Raizer J.J., Malkin M.G., Bazylewicz K.A., Abrey L.E. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol. 2002, 4:39-43.
63. Kickingereder P., Wiestler B., Burth S., Wick A., Nowosielski M., Heiland S., et al. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol. 2015, 17:1139-1147.
64. Kickingereder P., Wiestler B., Graf M., Heiland S., Schlemmer H.P., Wick W., et al. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab. J. Neurooncol. 2015, 121:373-380.
65. Kong D.S., Lee J.I., Kim W.S., Son M.J., Lim do H., Kim S.T., et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol. Rep. 2006, 16:1117-1121.
66. Kong D.-S., Lee J.-I., Kim J.H., Kim S.T., Kim W.S., Suh Y.-L., et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 2010, 12:289-296.
67. Kreisl T.N., Kim L., Moore K., Duic P., Royce C., Stroud I., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:740-745.
68. Kreisl T., Lassman A., Mischel P., Rosen N., Scher H., Teruya-Feldstein J., et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol. 2009, 92:99-105.
69. Kreisl T.N., McNeill K.A., Sul J., Iwamoto F.M., Shih J., Fine H.A. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol. 2012, 14:1519-1526.
70. Kreisl T., Smith P., Sul J., Salgado C., Iwamoto F., Shih J., et al. Continuous daily sunitinib for recurrent glioblastoma. J. Neurooncol. 2013, 111:41-48.
71. Lamborn K.R., Yung W.K., Chang S.M., Wen P.Y., Cloughesy T.F., DeAngelis L.M., et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008, 10:162-170.
72. Lassen U., Sorensen M., Gaziel T.B., Hasselbalch B., Poulsen H.S. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res. 2013, 33:1657-1660.
73. Lassen U., Chinot O.L., McBain C., Mau-Sorensen M., Larsen V.A., Barrie M., et al. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro Oncol. 2015, 17:1007-1015.
74. Lassen U., Mau-Soerensen M., Kung L., Wen P.Y., Lee E.Q., Plotkin S.R., et al. A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM). J. Clin. Oncol. 2015, 33:33.
75. Lassman A.B., Pugh S.L., Gilbert M.R., Aldape K.D., Geinoz S., Beumer J.H., et al. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 2015, 17:992-998.
76. Lee E.Q., Reardon D.A., Schiff D., Drappatz J., Muzikansky A., Grimm S.A., et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015, 17:862-867.
77. Macdonald D.R., Cascino T.L., Schold S.C., Cairncross J.G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 1990, 8:1277-1280.
78. Malmstrom A., Gronberg B.H., Marosi C., Stupp R., Frappaz D., Schultz H., et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012, 13:916-926.
79. McNamara M.G., Lwin Z., Jiang H., Templeton A.J., Zadeh G., Bernstein M., et al. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. J. Neurooncol. 2014, 117:147-152.
80. Minniti G., Agolli L., Falco T., Scaringi C., Lanzetta G., Caporello P., et al. Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. J. Neurooncol. 2015, 122:559-566.
81. 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. Radiat. Oncol. 2014, 9:181.
82. Moller S., Grunnet K., Hansen S., Schultz H., Holmberg M., Sorensen M., et al. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol. 2012, 51:797-804.
83. Muhic A., Poulsen H., Sorensen M., Grunnet K., Lassen U. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J. Neurooncol. 2013, 111:205-212.
84. 6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn. J. Clin. Oncol. 2007, 37:897-906.
85. Nagane M., Nishikawa R., Narita Y., Kobayashi H., Takano S., Shinoura N., et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn. J. Clin. Oncol. 2012, 42:887-895.
86. Nava F., Tramacere I., Fittipaldo A., Bruzzone M.G., Dimeco F., Fariselli L., et al. Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol. 2014, 16:719-727.
87. Norden A.D., Lesser G.J., Drappatz J., Ligon K.L., Hammond S.N., Lee E.Q., et al. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013, 15:930-935.
88. Pan E., Yu D., Yue B., Potthast L., Chowdhary S., Smith P., et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J. Neurooncol. 2012, 110:111-118.
89. Park J.K., Hodges T., Arko L., Shen M., Dello Iacono D., McNabb A., et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J. Clin. Oncol. 2010, 28:3838-3843.
90. Park C.K., Kim J.H., Nam D.H., Kim C.Y., Chung S.B., Kim Y.H., et al. A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. Neuro Oncol. 2013, 15:1096-1101.
91. Peereboom D.M., Ahluwalia M.S., Ye X., Supko J.G., Hilderbrand S.L., Phuphanich S., et al. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 2013, 15:490-496.
92. Perry J.R., Belanger K., Mason W.P., Fulton D., Kavan P., Easaw J., et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 2010, 28:2051-2057.
93. Pitz M.W., Eisenhauer E.A., MacNeil M.V., Thiessen B., Easaw J.C., Macdonald D.R., et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 2015, 17:1270-1274.
94. Prados M.D., Yung W.K., Fine H.A., Greenberg H.S., Junck L., Chang S.M., et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol. 2004, 6:33-37.
95. Puduvalli V., Wu J., Yuan Y., Armstrong T., Groves M.D., Raizer J., et al. Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). J. Clin. Oncol. 2015, 33. (suppl; abstr 2012).
96. Quinn J.A., Jiang S.X., Reardon D.A., Desjardins A., Vredenburgh J.J., Rich J.N., et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol. 2009, 27:1262-1267.
97. Radbruch A., Eidel O., Wiestler B., Paech D., Burth S., Kickingereder P., et al. Quantification of tumor vessels in glioblastoma patients using time-of-flight angiography at 7 Tesla: a feasibility study. PLoS One 2014, 9:e110727.
98. Raizer J.J., Grimm S., Chamberlain M.C., Nicholas M.K., Chandler J.P., Muro K., et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010, 116:5297-5305.
99. Ratai E.M., Zhang Z., Snyder B.S., Boxerman J.L., Safriel Y., McKinstry R.C., et al. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro Oncol. 2013, 15:936-944.
100. Reardon D.A., Quinn J.A., Rich J.N., Desjardins A., Vredenburgh J., Gururangan S., et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005, 104:1478-1486.
101. Reardon D.A., Fink K.L., Mikkelsen T., Cloughesy T.F., O'Neill A., Plotkin S., et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 2008, 26:5610-5617.
102. Reardon D.A., Desjardins A., Vredenburgh J.J., Gururangan S., Sampson J.H., Sathornsumetee S., et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br. J. Cancer 2009, 101:1986-1994.
103. Reardon D.A., Desjardins A., Peters K., Gururangan S., Sampson J., Rich J.N., et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J. Neurooncol. 2011, 103:371-379.
104. Reardon D.A., Vredenburgh J.J., Desjardins A., Peters K., Gururangan S., Sampson J.H., et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J. Neurooncol. 2011, 101:57-66.
105. Reardon D.A., Desjardins A., Peters K.B., Gururangan S., Sampson J.H., McLendon R.E., et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J. Neurooncol. 2012, 107:155-164.
106. Reardon D.A., Groves M.D., Wen P.Y., Nabors L., Mikkelsen T., Rosenfeld S., et al. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin. Cancer Res. 2013, 19:900-908.
107. Reardon D.A., Nabors L.B., Mason W.P., Perry J.R., Shapiro W., Kavan P., et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015, 17:430-439.
108. Reardon D.A., Schuster J., Tran D.D., Fink K., Nabors L.B., Li G., et al. ReACT: overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J. Clin. Oncol. 2015, 33. (suppl; abstr 2009).
109. Rieger J., Bahr O., Maurer G.D., Hattingen E., Franz K., Brucker D., et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int. J. Oncol. 2014, 44:1843-1852.
110. Ryu S., Buatti J.M., Morris A., Kalkanis S.N., Ryken T.C., Olson J.J., et al. The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2014, 118:489-499.
111. Sampson J., Vlahovic G., Sahebjam S., Padula Omuro A.M., Baehring J.M., Hafler D.A., et al. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. J. Clin. Oncol. 2015, 33. (suppl; abstr 3010).
112. Santoni M., Paccapelo A., Burattini L., Bianconi M., Cardinali M., Fabbietti L., et al. Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: a phase II study. Oncol. Lett. 2012, 4:799-801.
113. Sathornsumetee S., Desjardins A., Vredenburgh J.J., McLendon R.E., Marcello J., Herndon J.E., et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010, 12:1300-1310.
114. Schijns V.E., Pretto C., Devillers L., Pierre D., Hofman F.M., Chen T.C., et al. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine 2015, 33:2690-2696.
115. Schmainda K.M., Prah M., Connelly J., Rand S.D., Hoffman R.G., Mueller W., et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol. 2014, 16:880-888.
116. Scoccianti S., Detti B., Sardaro A., Iannalfi A., Meattini I., Leonulli B.G., et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 2008, 19:613-620.
117. Sepulveda J.M., Belda-Iniesta C., Gil-Gil M., Perez-Segura P., Berrocal A., Reynes G., et al. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. Clin. Transl. Oncol. 2015, 17:743-750.
118. Silvani A., Eoli M., Salmaggi A., Lamperti E., Maccagnano E., Broggi G., et al. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J. Neurooncol. 2004, 66:203-208.
119. Soffietti R., Trevisan E., Bertero L., Cassoni P., Morra I., Fabrini M.G., et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J. Neurooncol. 2014, 116:533-541.
120. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 2005, 7:369. (abstr 342).
121. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
122. Stupp R., Tosoni A., Bromberg J.E., Hau P., Campone M., Gijtenbeek J., et al. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma: a phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann. Oncol. 2011, 22:2144-2149.
123. Stupp R., Wong E.T., Kanner A.A., Steinberg D., Engelhard H., Heidecke V., et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 2012, 48:2192-2202.
124. Suchorska B., Weller M., Tabatabai G., Senft C., Hau P., Sabel M., et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma results from the DIRECTOR trial. Neurosurgery 2015, 62(Suppl. 1):209.
125. Taal W., Oosterkamp H.M., Walenkamp A.M., Dubbink H.J., Beerepoot L.V., Hanse M.C., et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014, 15:943-953.
126. Verhoeff J.J., Lavini C., van Linde M.E., Stalpers L.J., Majoie C.B., Reijneveld J.C., et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann. Oncol. 2010, 21:1723-1727.
127. Vredenburgh J.J., Desjardins A., Herndon J.E., Marcello J., Reardon D.A., Quinn J.A., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007, 25:4722-4729.
128. Vredenburgh J.J., Desjardins A., Herndon J.E., Dowell J.M., Reardon D.A., Quinn J.A., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007, 13:1253-1259.
129. van den Bent M.J., Brandes A.A., Rampling R., Kouwenhoven M.C., Kros J.M., Carpentier A.F., et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 2009, 27:1268-1274.
130. Weathers S., Han S., Liu D., Conrad C.A., Gilbert M.R., Loghin M.E., et al. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J. Clin. Oncol. 2015, 33. (suppl; abstr 2005).
131. Weller M., Cloughesy T., Perry J.R., Wick W. Standards of care for treatment of recurrent glioblastoma-are we there yet. Neuro Oncol. 2013, 15:4-27.
132. Weller M., van den Bent M., Hopkins K., Tonn J.C., Stupp R., Falini A., et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014, 15:e395-403.
133. Weller M., Tabatabai G., Kastner B., Felsberg J., Steinbach J.P., Wick A., et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin. Cancer Res. 2015, 21:2057-2064.
134. Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 2010, 28:1963-1972.
135. Wen P.Y., Prados M., Schiff D., Reardon D.A., Cloughesy T., Mikkelsen T., et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J. Clin. Oncol. 2010, 28. (suppl; abstr 2006).
136. Wen P.Y., Schiff D., Cloughesy T.F., Raizer J.J., Laterra J., Smitt M., et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011, 13:437-446.
137. Wen P.Y. American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev. Anticancer Ther. 2010, 10:1367-1369.
138. Wick W., Steinbach J.P., Kuker W.M., Dichgans J., Bamberg M., Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004, 62:2113-2115.
139. Wick A., Felsberg J., Steinbach J.P., Herrlinger U., Platten M., Blaschke B., et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J. Clin. Oncol. 2007, 25:3357-3361.
140. Wick W., Puduvalli V.K., Chamberlain M.C., van den Bent M.J., Carpentier A.F., Cher L.M., et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 2010, 28:1168-1174.
141. Wick W., Platten M., Meisner C., Felsberg J., Tabatabai G., Simon M., et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012, 13:707-715.
142. Wick W., Fricke H., Junge K., Kobyakov G., Martens T., Heese O., et al. A phase II, randomized, study of weekly APG101 + reirradiation versus reirradiation in progressive glioblastoma. Clin. Cancer Res. 2014, 20:6304-6313.
143. Wick W., Brandes A., Gorlia T., Bendszus M., Sahm F., Taal W., et al. Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial. Neuro Oncol. 2015, 17. (suppl. 5; LB05).
144. Woernle C.M., Peus D., Hofer S., Rushing E.J., Held U., Bozinov O., et al. Efficacy of surgery and further treatment of progressive glioblastoma. World Neurosurg. 2015, 84:301-307.
145. Yong R.L., Wu T., Mihatov N., Shen M.J., Brown M.A., Zaghloul K.A., et al. Residual tumor volume and patient survival following reoperation for recurrent glioblastoma. J. Neurosurg. 2014, 121:802-809.
146. Yung W.K., Albright R.E., Olson J., Fredericks R., Fink K., Prados M.D., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 2000, 83:588-593.